T 0362/18 (GnRH antagonist/FERRING) of 15.02.2019
- European Case Law Identifier
- ECLI:EP:BA:2019:T036218.20190215
- Date of decision
- 15 February 2019
- Case number
- T 0362/18
- Petition for review of
- -
- Application number
- 12165896.7
- IPC class
- A61K 38/09A61P 35/00A61K 38/08
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Method of treating prostate cancer with the GnRH antagonist degarelix
- Applicant name
- Ferring B.V.
- Opponent name
- Fresenius Kabi Deutschland GmbH
Generics [UK] Limited (trading as Mylan) - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 108European Patent Convention R 101(1)European Patent Convention R 99(2)
- Keywords
- Admissibility of appeal - missing statement of grounds
- Catchword
- -
- Cited cases
- T 1042/07
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is rejected as inadmissible.